KGF-2 Alleviates Dry Eye Disease by Regulating the HMGB1/TLR4 Pathway
KGF-2 demonstrated protective effects in both in vivo and in vitro DED models by modulating the HMGB1/TLR4 pathway. These findings suggest its potential as a therapeutic agent for DED, warranting further clinical investigation in this regard.
Authors
- Xiujuan Lv
- Zhiqiang Xu (ORCID: https://orcid.org/0000-0001-7740-8360)
- Linzhi Wei (ORCID: https://orcid.org/0000-0002-5066-6420)
- Yuzhou Wang (ORCID: https://orcid.org/0000-0001-9324-954X)
- Kaiyan Huang (ORCID: https://orcid.org/0009-0005-1635-9354)
- Jia Qu (ORCID: https://orcid.org/0000-0001-5729-567X)
- Yang Lu (ORCID: https://orcid.org/0009-0000-8172-4075)
- Liang Hu (ORCID: https://orcid.org/0000-0001-9884-0312)
- Fan Lü (ORCID: https://orcid.org/0000-0002-8794-6944)
- S. P. Wen (ORCID: https://orcid.org/0000-0002-7889-3537)
- Yizhou Shi
Institutions
- Wenzhou Medical University (CN)
- Affiliated Eye Hospital of Wenzhou Medical College (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1167/iovs.66.4.28
- Citations
- 2
- Primary Topic
- Ocular Surface and Contact Lens
- Type
- article
- Field-Weighted Citation Impact
- 3.76